Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etodolac, aspirin, and gastrointestinal microbleeding.

J D Arnold, J F Mullane, D M Hayden

    Clinical Pharmacology and Therapeutics
    |May 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The impact of an online self-management programme for type 2 diabetes. The BEATdiabetes prospective service evaluation.

    Primary care diabetes·2025
    Same author

    The development of an EU-wide nutrition and physical activity expert knowledge base to support a personalised mobile application across various EU population groups.

    Nutrition bulletin·2024
    Same author

    Laryngeal Phthisis.

    The Independent practitioner·2023
    Same author

    Ottorrhœ-Its Rational Treatment.

    Hall's journal of health·2022
    Same author

    The Value of Local Treatment in Syphilitic Ulceration of the Larynx and Pharynx.

    Atlanta medical and surgical journal·2022
    Same author

    Long-term changes in nutritional status and body composition in patients with malignant pancreatic disease - A systematic review.

    Clinical nutrition ESPEN·2021
    Same journal

    Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.

    Clinical pharmacology and therapeutics·2026
    Same journal

    From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI.

    Clinical pharmacology and therapeutics·2026
    Same journal

    The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Etodolac, a nonsteroidal anti-inflammatory drug, did not cause significant gastrointestinal (GI) microbleeding in healthy men. Aspirin, however, was associated with notable GI blood loss in this study.

    Area of Science:

    • Pharmacology
    • Gastroenterology
    • Clinical Research

    Background:

    • Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
    • Gastrointestinal (GI) microbleeding is a known side effect of some NSAIDs.
    • Quantitative assessment of GI microbleeding is crucial for drug safety evaluation.

    Purpose of the Study:

    • To quantitatively assess the effects of etodolac on gastrointestinal (GI) microbleeding in healthy adult men.
    • To compare the GI microbleeding potential of etodolac with aspirin and placebo.

    Main Methods:

    • Two parallel-group studies were conducted in healthy adult men.
    • Radiolabeled (51Cr) erythrocyte method was used to estimate daily GI blood loss.
    • Dosing regimens included etodolac (600-1200 mg/day), aspirin (2600 mg/day), and placebo over specified treatment periods.

    Related Experiment Videos

    Main Results:

    • Etodolac, at doses of 600, 800, and 1200 mg/day, did not induce significant GI microbleeding.
    • Aspirin (2600 mg/day) was associated with significant GI blood loss in both studies.
    • No significant increase in GI blood loss was observed with etodolac compared to placebo.

    Conclusions:

    • Etodolac demonstrates a favorable gastrointestinal safety profile regarding microbleeding.
    • Etodolac appears to be a safer alternative to aspirin concerning NSAID-induced GI blood loss.
    • Further clinical studies may be warranted to confirm these findings in broader populations.